{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:15:08Z","timestamp":1792523708536,"version":"4.5.0"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Highly sensitized kidney transplant candidates are difficult to transplant because anti-human leukocyte antigen (HLA) sensitization restricts access to immunologically compatible organs, as transplantation across donor-specific antibodies (DSA) increases the risk of antibody-mediated rejection (AMR) and premature graft loss. Management should therefore move beyond antibody characteristics alone and assess whether a compatible offer remains realistic for the individual patient within the relevant allocation system. This review proposes a sequential, compatibility-first access framework. Compatible transplantation should remain the preferred goal and may be achieved through kidney paired exchange, compatible living-donor pathways, sensitization-aware prioritization, and dedicated allocation programs. International experience shows that allocation design can mitigate access restrictions for moderately sensitized candidates, while highly sensitized candidates require more targeted prioritization. The Eurotransplant acceptable mismatch program exemplifies this principle by combining expert-defined acceptable antigens with allocation priority, thereby promoting compatible transplantation with excellent outcomes in a restricted highly sensitized cohort without therapeutic crossing of the immunological barrier. Compatible pathways should be tried and optimized before intervention-based strategies are considered. In candidates without a realistic compatible option within a reasonable timeframe, conventional desensitization, risk-adapted delisting of selected unacceptable antigens, or imlifidase-enabled transplantation may become justified, particularly when severe dialysis-related problems exist. Imlifidase can rapidly enable selected positive-crossmatch deceased-donor transplantation, but AMR remains frequent and strict governance, candidate selection, and posttransplant surveillance are mandatory. Novel AMR treatments, including CD38-directed therapies, may improve the long-term feasibility of barrier-crossing strategies. Emerging B-cell and plasma-cell targeting approaches, including interleukin-6-, CAR-T-cell-, and BCMA-directed strategies, remain investigational. Optimal care requires integrating immunologic precision, allocation design, intervention thresholds, and structured monitoring into an individualized compatibility-first strategy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1868642","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:25:44Z","timestamp":1782793544000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Highly sensitized kidney transplant candidates: integrating acceptable mismatch, desensitization, imlifidase, and emerging immune-cell targeting strategies"],"prefix":"10.3389","volume":"17","author":[{"given":"Stefan","family":"Reuter","sequence":"first","affiliation":[{"name":"Department of Internal Medicine D, Transplant Nephrology, University of Muenster","place":["Muenster, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Lachmann","sequence":"additional","affiliation":[{"name":"Institute of Transfusion Medicine, Tissue Typing\/Human Leukocyte Antigen (HLA), Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"de Ferrante","sequence":"additional","affiliation":[{"name":"Eurotransplant International Foundation","place":["Leiden, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg A.","family":"B\u00f6hmig","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Budde","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Medical Intensive Care, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05930615","article-title":"Approach to the highly sensitized kidney transplant candidate","volume":"11","author":"Keith","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000000000000509","article-title":"New therapies for highly sensitized patients on the waiting list","volume":"5","author":"Vo","year":"2024","journal-title":"Kidney360"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13751","article-title":"Managing highly sensitized renal transplant candidates in the era of kidney paired donation and the new kidney allocation system: is there still a role for desensitization","volume":"33","author":"Schinstock","year":"2019","journal-title":"Clin Transplant"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2022.10511","article-title":"European guideline for the management of kidney transplant patients with HLA antibodies: by the European Society for Organ Transplantation Working Group","volume":"35","author":"Mamode","year":"2022","journal-title":"Transpl Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.687254","article-title":"Highly sensitized patients are well served by receiving a compatible organ offer based on acceptable mismatches","volume":"12","author":"Heidt","year":"2021","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.kint.2017.07.018","article-title":"Kidney allocation based on proven acceptable antigens results in superior graft survival in highly sensitized patients","volume":"93","author":"Heidt","year":"2018","journal-title":"Kidney Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15486","article-title":"Allocation to highly sensitized patients based on acceptable mismatches results in low rejection rates comparable to nonsensitized patients","volume":"19","author":"Heidt","year":"2019","journal-title":"Am J Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000536533","article-title":"Positive long-term outcome of kidney allocation via acceptable mismatch program in highly sensitized patients","volume":"51","author":"Strehler","year":"2024","journal-title":"Transfus Med Hemother"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2020.101354","article-title":"A Europe wide acceptable mismatch program will enable transplantation of long waiting highly sensitised patients with a compatible donor","volume":"64","author":"Mumford","year":"2021","journal-title":"Transpl Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612567","article-title":"IgG endopeptidase in highly sensitized patients undergoing transplantation","volume":"377","author":"Jordan","year":"2017","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2023.11244","article-title":"Imlifidase for kidney transplantation of highly sensitized patients with a positive crossmatch: the French consensus guidelines","volume":"36","author":"Couzi","year":"2023","journal-title":"Transpl Int"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2024.13886","article-title":"Desensitization with imlifidase for HLA-incompatible deceased donor kidney transplantation: a Delphi international expert consensus","volume":"37","author":"Furian","year":"2025","journal-title":"Transpl Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000005388","article-title":"Belgian consensus guidelines within Eurotransplant on imlifidase-enabled deceased donor kidney transplantation in highly sensitized patients","volume":"109","author":"Kuypers","year":"2025","journal-title":"Transplantation"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.02.008","article-title":"CAR T-cell therapy-paving the way for sensitized kidney transplant patients","volume":"105","author":"Jarmi","year":"2024","journal-title":"Kidney Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2024.111180","article-title":"Cars pick up another passenger: organ transplantation","volume":"86","author":"Papadaki","year":"2025","journal-title":"Hum Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-025-06884-1","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy in a highly sensitized patient with focal and segmental glomerulosclerosis","volume":"40","author":"Guzzo","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2026.01.020","article-title":"B-cell maturation antigen-targeted T-cell engager therapy combined with B-cell depletion for treatment of refractory HLA sensitization","volume":"109","author":"Leon","year":"2026","journal-title":"Kidney Int"},{"key":"B18","volume-title":"Eurotransplant Manual. Chapter 10: Histocompatibility Testing. Version 5.5","year":"2024"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02927.x","article-title":"Calculated PRA (CPRA): the new measure of sensitization for transplant candidates","volume":"10","author":"Cecka","year":"2010","journal-title":"Am J Transplant"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2024.12475","article-title":"European consensus on the management of sensitized kidney transplant recipients: a Delphi study","volume":"37","author":"Furian","year":"2024","journal-title":"Transpl Int"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2022.10138","article-title":"Alloimmune risk stratification for kidney transplant rejection","volume":"35","author":"Bestard","year":"2022","journal-title":"Transpl Int"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000004687","article-title":"Immunized patients face reduced access to transplantation in the Eurotransplant kidney allocation system","volume":"107","author":"de Ferrante","year":"2023","journal-title":"Transplantation"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000004238","article-title":"Impact of sensitization on waiting time prior to kidney transplantation in Germany","volume":"106","author":"Zecher","year":"2022","journal-title":"Transplantation"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2026.106340","article-title":"Sensitization and deceased-donor kidney transplant access in France","volume":"11","author":"Bertrand","year":"2026","journal-title":"Kidney Int Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1508380","article-title":"Survival benefit with kidney transplants from HLA-incompatible live donors","volume":"374","author":"Orandi","year":"2016","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.21926\/obm.transplant.2102143","article-title":"Beyond CPRA: identifying sensitized kidney candidates with markedly low access to deceased donor transplantation by granular CPRA and blood type","volume":"5","author":"Maldonado","year":"2021","journal-title":"OBM Transplant"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14946","article-title":"The real unmet need: a multifactorial approach for identifying sensitized kidney candidates with low access to transplant","volume":"37","author":"Maldonado","year":"2023","journal-title":"Clin Transplant"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.1988.tb01647.x","article-title":"Matchability in kidney transplantation","volume":"32","author":"Gilks","year":"1988","journal-title":"Tissue Antigens"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s40472-020-00270-6","article-title":"Overview of the evolution of the UK kidney allocation schemes","volume":"7","author":"Watson","year":"2020","journal-title":"Curr Transpl Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001862","article-title":"Association between donor-recipient matchability, access to transplantation, and posttransplant outcomes","volume":"11","author":"Lalji","year":"2025","journal-title":"Transplant Direct"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2011.12.049","article-title":"Effects of different sensitization events on HLA alloimmunization in solid organ transplantation patients","volume":"44","author":"Hyun","year":"2012","journal-title":"Transplant Proc"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2015.03.014","article-title":"Effect of different sensitization events on HLA alloimmunization in kidney transplantation candidates","volume":"47","author":"Lopes","year":"2015","journal-title":"Transplant Proc"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.6002\/ect.2016.0292","article-title":"Effect of single sensitization event on human leukocyte antigen alloimmunization in kidney transplant candidates: a single-center experience","volume":"16","author":"Resse","year":"2018","journal-title":"Exp Clin Transplant"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20211493","article-title":"Toward an understanding of allogeneic conflict in pregnancy and transplantation","volume":"219","author":"Durgam","year":"2022","journal-title":"J Exp Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001203","article-title":"Interpreting anti-HLA antibody testing data: a practical guide for physicians","volume":"100","author":"Schinstock","year":"2016","journal-title":"Transplantation"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2017.05.007","article-title":"Understanding solid-phase HLA antibody assays and the value of MFI","volume":"78","author":"Sullivan","year":"2017","journal-title":"Hum Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14752","article-title":"Sensitization in transplantation: assessment of risk (STAR) 2017 Working Group Meeting Report","volume":"18","author":"Tambur","year":"2018","journal-title":"Am J Transplant"},{"key":"B38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/TP.0b013e31827a19cc","article-title":"Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation","volume":"95","author":"Tait","year":"2013","journal-title":"Transplantation"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001817","article-title":"HLA diagnostics: evaluating DSA strength by titration","volume":"102","author":"Tambur","year":"2018","journal-title":"Transplantation"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134475","article-title":"Clinical outcome of kidney transplant recipients with C1q-binding de novo donor specific antibodies: a single-center experience","volume":"12","author":"Marinaki","year":"2023","journal-title":"J Clin Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics16020207","article-title":"IgG subclass profiles of HLA antibodies enhance prediction of C1q-binding in kidney transplant recipients","volume":"16","author":"Lee","year":"2026","journal-title":"Diagnostics (Basel)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000129260.86766.67","article-title":"The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome","volume":"78","author":"Claas","year":"2004","journal-title":"Transplantation"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.04.031","article-title":"A multicenter prospective cohort study evaluating impact of an active delisting strategy to enable kidney transplantation in wait-listed candidates with calculated panel reactive antibody \u2265 99.9","volume":"108","author":"Cucchiari","year":"2025","journal-title":"Kidney Int"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707894","article-title":"Rituximab and intravenous immune globulin for desensitization during renal transplantation","volume":"359","author":"Vo","year":"2008","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181d21e7f","article-title":"Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation","volume":"89","author":"Vo","year":"2010","journal-title":"Transplantation"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002635","article-title":"Desensitization using bortezomib and high-dose immunoglobulin increases rate of deceased donor kidney transplantation","volume":"95","author":"Jeong","year":"2016","journal-title":"Med (Baltimore)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012376","article-title":"Desensitization in HLA-incompatible kidney recipients and survival","volume":"365","author":"Montgomery","year":"2011","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000296","article-title":"Human leukocyte antigen-incompatible kidney transplantation after \"desensitization\"--hope and reality","volume":"98","author":"Neumayer","year":"2014","journal-title":"Transplantation"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000298","article-title":"Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation","volume":"98","author":"Orandi","year":"2014","journal-title":"Transplantation"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001139","article-title":"Marginal impact of tocilizumab monotherapy on anti-HLA alloantibodies in highly sensitized kidney transplant candidates","volume":"7","author":"Daligault","year":"2021","journal-title":"Transplant Direct"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12020424","article-title":"Tocilizumab evaluation in HLA-desensitization before kidney transplantation as an add-on therapy to apheresis: The TETRA study","volume":"12","author":"Jouve","year":"2023","journal-title":"J Clin Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16926","article-title":"Clazakizumab for desensitization in highly sensitized patients awaiting transplantation","volume":"22","author":"Vo","year":"2022","journal-title":"Am J Transplant"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000000000287","article-title":"Isatuximab monotherapy for desensitization in highly sensitized patients awaiting kidney transplant","volume":"35","author":"Vincenti","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.08.020","article-title":"Open-label phase 1\/2 study of daratumumab-based desensitization before kidney transplantation","volume":"9","author":"Pilon","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15514","article-title":"Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant","volume":"19","author":"Redfield","year":"2019","journal-title":"Am J Transplant"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003686","article-title":"Obinutuzumab in kidney transplantation: Effect on B-cell counts and crossmatch tests","volume":"106","author":"Nasrallah","year":"2022","journal-title":"Transplantation"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003496","article-title":"Imlifidase desensitization in crossmatch-positive, highly sensitized kidney transplant recipients: Results of an international phase 2 trial (Highdes)","volume":"105","author":"Jordan","year":"2021","journal-title":"Transplantation"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16754","article-title":"Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients","volume":"21","author":"Kjellman","year":"2021","journal-title":"Am J Transplant"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.07.024","article-title":"Imlifidase in highly sensitized kidney transplant recipients with a positive crossmatch against a deceased donor","volume":"9","author":"Kamar","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2025.15425","article-title":"Five years follow-up of imlifidase desensitized kidney transplant recipients","volume":"38","author":"Lorant","year":"2025","journal-title":"Transpl Int"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001752","article-title":"Clinical outcomes and donor-specific antibody rebound 5 y after kidney transplant enabled by imlifidase desensitization","volume":"11","author":"Jaffe","year":"2025","journal-title":"Transplant Direct"},{"key":"B62","volume-title":"Idefirix (Imlifidase): EPAR - Product Information","year":"2025"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2025.100919","article-title":"Spanish guidelines for kidney transplantation in highly sensitized patients with donor-specific anti-HLA antibodies","volume":"39","author":"Mancebo","year":"2025","journal-title":"Transplant Rev (Orlando)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1159\/000538513","article-title":"Successful desensitization with imlifidase and daratumumab in a highly immunized, crossmatch positive, blood group-incompatible living-donor re-transplant recipient with systemic lupus erythematosus and antiphospholipid syndrome","volume":"51","author":"Schrezenmeier","year":"2024","journal-title":"Transfus Med Hemother"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400763","article-title":"A randomized phase 2 trial of felzartamab in antibody-mediated rejection","volume":"391","author":"Mayer","year":"2024","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf097","article-title":"Antibody-mediated rejection-treatment standard","volume":"40","author":"B\u00f6hmig","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2025.14343","article-title":"Targeting CD38 in antibody-mediated rejection","volume":"38","author":"Mayer","year":"2025","journal-title":"Transpl Int"},{"key":"B68","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/ndt\/gfae160","article-title":"Chimeric HLA antibody receptor T cell therapy for humoral transplant rejection","volume":"40","author":"Arana","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B69","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - A case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2517277","article-title":"Kidney transplantation after clearing anti-HLA antibodies with CD19 CAR T cells","volume":"394","author":"Schrezenmeier","year":"2026","journal-title":"N Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2513428","article-title":"Kidney transplantation in two highly sensitized candidates after CAR T-cell therapy","volume":"394","author":"Bhoj","year":"2026","journal-title":"N Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2026.01.032","article-title":"Tiny warriors, big impact: Targeted immunotherapy in kidney diseases","volume":"109","author":"Kurzhagen","year":"2026","journal-title":"Kidney Int"},{"key":"B73","volume-title":"NCT07350837. CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Adult Participants With End-Stage Kidney Disease","year":"2025"},{"key":"B74","volume-title":"NCT06056102. CAR-T Cell Therapy for Desensitization in Kidney Transplantation","year":"2025"},{"key":"B75","volume-title":"NCT05092347. A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease Who Need a Kidney Transplant and are Highly Sensitized to Human Leukocyte Antigen","year":"2025"},{"key":"B76","volume-title":"NCT05106387. A Noninterventional Extension Study for Patients Treated in Study R5459-RT-1944 With Vonsetamig (BCMA X CD3 Bispecific Antibody) Who Receive a Kidney Transplant","year":"2025"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2026.02.029","article-title":"Targeting B cells in immune-mediated kidney diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"110","author":"Floege","year":"2026","journal-title":"Kidney Int"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1831754","article-title":"ABO-incompatible kidney transplantation with high isoagglutinin titres: Practice pattern and problem solving: A German multi-centre survey","volume":"17","author":"Reuter","year":"2026","journal-title":"Front Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1846251","article-title":"Risk-adapted HLA delisting and imlifidase-enabled deceased-donor kidney transplantation in highly sensitized kidney transplant candidates: A German expert consensus report","volume":"17","author":"Reuter","year":"2026","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1868642\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:25:46Z","timestamp":1782793546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1868642\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":79,"alternative-id":["10.3389\/fimmu.2026.1868642"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1868642","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"article-number":"1868642"}}